SPR965

SPR965 is an orally bioavailable, small molecule, dual inhibitor of **phosphatidylinositol 3 kinase (PI3K)**—primarily the alpha isoform—and **mammalian target of rapamycin (mTOR) Complex 1/2 (C1/C2)**[1][3][4][7]. It has demonstrated potent anti-tumorigenic activity in preclinical models of a variety of solid tumors, including ovarian cancer, by causing cell cycle arrest, inducing cellular stress, and inhibiting tumor proliferation and growth[1][4]. SPR965 exerts its effects by downregulating the phosphorylation of AKT and S6 proteins, reducing markers such as Ki67 and VEGF, and modulating epithelial–mesenchymal transition[1][4]. The compound is being developed by Sphaera Pharma and is currently in preclinical development for solid tumors[3][4].